Talphera’s (TLPH) “Buy” Rating Reiterated at HC Wainwright

Talphera (NASDAQ:TLPH)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $3.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 275.00% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. Westpark Capital started coverage on Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Talphera has a consensus rating of “Hold” and a consensus target price of $3.00.

Talphera Price Performance

NASDAQ TLPH opened at $0.80 on Friday. The stock’s fifty day moving average price is $0.81 and its 200 day moving average price is $0.95. Talphera has a 1 year low of $0.38 and a 1 year high of $1.57. The company has a market cap of $41.52 million, a price-to-earnings ratio of -2.58 and a beta of 0.76.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Insider Activity at Talphera

In other news, CEO Vincent J. Angotti acquired 213,310 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were bought at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the acquisition, the chief executive officer owned 800,705 shares in the company, valued at approximately $472,415.95. This represents a 36.31% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Talphera

Several institutional investors have recently bought and sold shares of the company. Cantor Fitzgerald L. P. acquired a new stake in Talphera in the 4th quarter worth about $658,000. Diadema Partners LP purchased a new position in Talphera in the 4th quarter worth approximately $156,000. Persistent Asset Partners Ltd purchased a new position in Talphera in the 4th quarter worth approximately $42,000. Mariner LLC lifted its stake in Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after purchasing an additional 33,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Talphera by 412.6% in the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after purchasing an additional 207,166 shares in the last quarter. 37.67% of the stock is currently owned by institutional investors and hedge funds.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.